{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:17:59Z","timestamp":1780445879500,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.msard.2012.10.002","type":"journal-article","created":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T08:34:52Z","timestamp":1354869292000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"2","author":[{"given":"Isabela T.","family":"Borges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin D.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Ohayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ostuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Shiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibiana","family":"Bielekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2012.10.002_bib1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrneurol.2009.41","article-title":"Imaging outcomes for neuroprotection and repair in multiple sclerosis trials","volume":"5","author":"Barkhof","year":"2009","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib2","doi-asserted-by":"crossref","unstructured":"Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Human Brain Mapping 2012;33(9):2062\u201371","DOI":"10.1002\/hbm.21344"},{"key":"10.1016\/j.msard.2012.10.002_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hbm.21279","article-title":"Longitudinal gray matter changes in multiple sclerosis-differential scanner and overall disease-related effects","volume":"33","author":"Bendfeldt","year":"2012","journal-title":"Human Brain Mapping"},{"key":"10.1016\/j.msard.2012.10.002_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.neuroimage.2011.12.070","article-title":"Multivariate pattern classification of gray matter pathology in multiple sclerosis","volume":"60","author":"Bendfeldt","year":"2012","journal-title":"NeuroImage"},{"key":"10.1016\/j.msard.2012.10.002_bib5","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.msard.2012.10.002_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/archneurol.2009.50","article-title":"Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis","volume":"66","author":"Bielekova","year":"2009","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib7","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/awh176","article-title":"Development of biomarkers in multiple sclerosis","volume":"127","author":"Bielekova","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.10.002_bib8","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318239f7ef","article-title":"Intrathecal effects of daclizumab treatment of multiple sclerosis","volume":"77","author":"Bielekova","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature07450","article-title":"Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis","volume":"456","author":"Bouskra","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.msard.2012.10.002_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/brain\/awf025","article-title":"Brain atrophy in clinically early relapsing-remitting multiple sclerosis","volume":"125","author":"Chard","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.10.002_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jmri.22214","article-title":"Reducing the impact of White matter lesions on automated measures of brain gray and white matter volumes","volume":"32","author":"Chard","year":"2010","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"10.1016\/j.msard.2012.10.002_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.42.3.527","article-title":"Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging","volume":"42","author":"Coffey","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000201183.87175.9f","article-title":"Ventricular enlargement in MS: one-year change at various stages of disease","volume":"66","author":"Dalton","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib14","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/WNL.0b013e3181e24136","article-title":"Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes","volume":"74","author":"De Stefano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneur.58.1.65","article-title":"Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability","volume":"58","author":"De Stefano","year":"2001","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/brain\/awg038","article-title":"Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis","volume":"126","author":"Filippi","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.10.002_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(04)17271-1","article-title":"Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"364","author":"Filippi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2012.10.002_bib18","unstructured":"Gelineau-Morel R, Tomassini V, Jenkinson M, Johansen-Berg H, Matthews PM, Palace J The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Human Brain Mapping, 10.1002\/hbm.21402, in press."},{"key":"10.1016\/j.msard.2012.10.002_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/01.WNL.0000149516.30155.B8","article-title":"Rate of brain atrophy in relapsing MS decreases during treatment with IFN beta-1a","volume":"64","author":"Hardmeier","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jmri.21648","article-title":"Caudate nuclei volume, diffusion tensor metrics, and T(2) relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: implications for understanding gray matter degeneration","volume":"29","author":"Hasan","year":"2009","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"10.1016\/j.msard.2012.10.002_bib21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/mrm.22515","article-title":"Human brain atlas-based volumetry and relaxometry: application to healthy development and natural aging","volume":"64","author":"Hasan","year":"2010","journal-title":"Magnetic Resonance in Medicine"},{"key":"10.1016\/j.msard.2012.10.002_bib22","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.10.002_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4049\/jimmunol.1100789","article-title":"Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis","volume":"187","author":"Jiang","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.msard.2012.10.002_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1474-4422(10)70131-9","article-title":"Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"9","author":"Kapoor","year":"2010","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2011.08.034","article-title":"Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study","volume":"312","author":"Khan","year":"2012","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.msard.2012.10.002_bib26","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/brain\/awf235","article-title":"Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time","volume":"125","author":"Kuhlmann","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.10.002_bib27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.10.002_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ana.22230","article-title":"A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis","volume":"68","author":"Magliozzi","year":"2010","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3174\/ajnr.A2430","article-title":"Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years","volume":"32","author":"Mesaros","year":"2011","journal-title":"American Journal of Neuroradiology"},{"issue":"11","key":"10.1016\/j.msard.2012.10.002_bib30","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/brain\/123.11.2256","article-title":"The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European study group on interferon beta-1b in secondary progressive multiple sclerosis","volume":"123","author":"Molyneux","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.10.002_bib50","unstructured":"Nakamura K, Rudick R, Lee JC, Foulds P, Fisher E. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis. American Academy of Neurology; Seattle, WA2010"},{"key":"10.1016\/j.msard.2012.10.002_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1552-6569.2008.00296.x","article-title":"Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis","volume":"19","author":"Neema","year":"2009","journal-title":"Journal of Neuroimaging"},{"key":"10.1016\/j.msard.2012.10.002_bib32","doi-asserted-by":"crossref","unstructured":"Perry JSA, Han S, Xu QG, Herman ML, Kennedy LB, Csako G, et al. Inhibition of LTi cell development by cd25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Science Translational Medicine. 2012;4(145). 10.1126\/scitranslmed.3004140","DOI":"10.1126\/scitranslmed.3004140"},{"key":"10.1016\/j.msard.2012.10.002_bib33","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archneur.1994.00540210046012","article-title":"A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood","volume":"51","author":"Pfefferbaum","year":"1994","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib34","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1212\/01.wnl.0000250267.85698.7a","article-title":"Gray matter involvement in multiple sclerosis","volume":"68","author":"Pirko","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib35","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/01.wnl.0000267662.41734.1f","article-title":"Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results","volume":"69","author":"Rose","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ana.20287","article-title":"Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody","volume":"56","author":"Rose","year":"2004","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/135245850000600601","article-title":"Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a","volume":"6","author":"Rudick","year":"2000","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2012.10.002_bib38","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.4049\/jimmunol.0802911","article-title":"Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells","volume":"183","author":"Schmutz","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.msard.2012.10.002_bib39","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/hbm.20566","article-title":"Nonrigid registration of multiple sclerosis brain images using lesion inpainting for morphometry or lesion mapping","volume":"30","author":"Sdika","year":"2009","journal-title":"Human Brain Mapping"},{"key":"10.1016\/j.msard.2012.10.002_bib40","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.neuroimage.2009.09.005","article-title":"A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions","volume":"49","author":"Shiee","year":"2010","journal-title":"NeuroImage"},{"key":"10.1016\/j.msard.2012.10.002_bib41","doi-asserted-by":"crossref","first-page":"e37049","DOI":"10.1371\/journal.pone.0037049","article-title":"Revisiting brain atrophy and its relationship to disability in multiple sclerosis","volume":"7","author":"Shiee","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2012.10.002_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2008.12.035","article-title":"Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry","volume":"282","author":"Tao","year":"2009","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.msard.2012.10.002_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/1352458503ms868oa","article-title":"Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years","volume":"9","author":"Turner","year":"2003","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2012.10.002_bib44","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm.2365","article-title":"A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy","volume":"17","author":"Wuest","year":"2011","journal-title":"Nature Medicine"},{"key":"10.1016\/j.msard.2012.10.002_bib45","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000069464.22267.95","article-title":"Thalamic neurodegeneration in relapsing-remitting multiple sclerosis","volume":"60","author":"Wylezinska","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1352458506070446","article-title":"Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy","volume":"13","author":"Zivadinov","year":"2007","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2012.10.002_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis","volume":"71","author":"Zivadinov","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.10.002_bib49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/jnnp.70.6.773","article-title":"A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis","volume":"70","author":"Zivadinov","year":"2001","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034812001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034812001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:35:23Z","timestamp":1761899723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034812001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S2211034812001265"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2012.10.002","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2012.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}